CAR--话题@MedSci

#CAR-#

459篇内容 | 2250人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1781505, encodeId=f2b41e8150598, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Biomedicines：“肿瘤克星”CAR-T疗法再升级！未来或能实现百病皆可CAR-T, objectType=article, longId=732571, objectId=0a3fe3257162, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a3fe3257162, replyNumber=0, likeNumber=76, createdTime=2022-10-12, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a3fe3257162, moduleTitle=Biomedicines：“肿瘤克星”CAR-T疗法再升级！未来或能实现百病皆可CAR-T, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a3fe3257162)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781443, encodeId=17e41e814438d, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=天价神药“CAR-T”首例患者已出院，第二款也获批！, objectType=article, longId=216718, objectId=8d75216e18c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d75216e18c6, replyNumber=0, likeNumber=64, createdTime=2022-05-14, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d75216e18c6, moduleTitle=天价神药“CAR-T”首例患者已出院，第二款也获批！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d75216e18c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781512, encodeId=830c1e815125a, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=突发：FDA暂停Beam公司基于碱基编辑的CAR-T疗法临床试验申请, objectType=article, longId=734269, objectId=c2dce342698f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2dce342698f, replyNumber=0, likeNumber=70, createdTime=2022-11-07, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2dce342698f, moduleTitle=突发：FDA暂停Beam公司基于碱基编辑的CAR-T疗法临床试验申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2dce342698f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781462, encodeId=afcd1e81462a5, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Nature：CAR-T之父论文：效果超过十年，CAR-T真的彻底治愈了癌症, objectType=article, longId=295114, objectId=e50529511433, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e50529511433, replyNumber=0, likeNumber=94, createdTime=2022-09-10, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e50529511433, moduleTitle=Nature：CAR-T之父论文：效果超过十年，CAR-T真的彻底治愈了癌症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e50529511433)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781465, encodeId=c27b1e814650a, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=由于患者死亡，CAR-T细胞疗法ATA2271的临床试验被暂停, objectType=article, longId=299319, objectId=aae0299319f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aae0299319f3, replyNumber=0, likeNumber=66, createdTime=2022-03-08, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aae0299319f3, moduleTitle=由于患者死亡，CAR-T细胞疗法ATA2271的临床试验被暂停, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aae0299319f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781450, encodeId=4f001e814501a, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=博生吉医药CD7靶向CAR-T细胞注射液获得美国FDA孤儿药资格认定, objectType=article, longId=220150, objectId=4aba220150d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4aba220150d9, replyNumber=0, likeNumber=98, createdTime=2022-02-04, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4aba220150d9, moduleTitle=博生吉医药CD7靶向CAR-T细胞注射液获得美国FDA孤儿药资格认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4aba220150d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781478, encodeId=1b481e8147854, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=AACR 2022：BioNTech的CAR-T细胞疗法治疗实体瘤，疗效确切, objectType=article, longId=724120, objectId=4f46e241201a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f46e241201a, replyNumber=0, likeNumber=80, createdTime=2023-01-25, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f46e241201a, moduleTitle=AACR 2022：BioNTech的CAR-T细胞疗法治疗实体瘤，疗效确切, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4f46e241201a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781504, encodeId=b43b1e8150417, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=【7月12日(周二)19:00星光奕奕】CAR-T中国病例分享——双打击病例专享会即将开始！, objectType=article, longId=732092, objectId=4f79e3209297, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f79e3209297, replyNumber=0, likeNumber=58, createdTime=2022-07-15, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f79e3209297, moduleTitle=【7月12日(周二)19:00星光奕奕】CAR-T中国病例分享——双打击病例专享会即将开始！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4f79e3209297)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781445, encodeId=ade01e8144580, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Blood：auto-HCT相比CAR-T疗法更适合用作获得部分缓解的DLCLC患者的巩固治疗！, objectType=article, longId=218037, objectId=c49c21803e09, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c49c21803e09, replyNumber=0, likeNumber=74, createdTime=2022-06-05, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c49c21803e09, moduleTitle=Blood：auto-HCT相比CAR-T疗法更适合用作获得部分缓解的DLCLC患者的巩固治疗！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c49c21803e09)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781457, encodeId=b0451e81457a5, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Nature Chemical Biology ：疯狂的想法：武装CAR-T细胞，使其成为生产抗癌药物的“微型药房”, objectType=article, longId=293584, objectId=b5d3293584a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b5d3293584a6, replyNumber=0, likeNumber=71, createdTime=2022-05-29, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b5d3293584a6, moduleTitle=Nature Chemical Biology ：疯狂的想法：武装CAR-T细胞，使其成为生产抗癌药物的“微型药房”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b5d3293584a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781495, encodeId=68ef1e8149590, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=CAR-T之父最新Nature论文：无需放化疗，合成IL-9受体增强T细胞疗法，治愈实体肿瘤, objectType=article, longId=729830, objectId=b041e298307f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b041e298307f, replyNumber=0, likeNumber=94, createdTime=2022-10-14, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b041e298307f, moduleTitle=CAR-T之父最新Nature论文：无需放化疗，合成IL-9受体增强T细胞疗法，治愈实体肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b041e298307f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781441, encodeId=17bd1e81441f9, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=科济药业发布2021年中期业绩自主研发 CAR-T候选品进入海外关键II期临床试验, objectType=article, longId=216260, objectId=c3532162608a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3532162608a, replyNumber=0, likeNumber=66, createdTime=2022-03-04, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3532162608a, moduleTitle=科济药业发布2021年中期业绩自主研发 CAR-T候选品进入海外关键II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c3532162608a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781486, encodeId=43251e8148641, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Nat Med：科济生物Claudin18.2 CAR-T细胞治疗实体瘤初获突破, objectType=article, longId=726548, objectId=07f5e2654866, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=07f5e2654866, replyNumber=0, likeNumber=78, createdTime=2023-01-12, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=07f5e2654866, moduleTitle=Nat Med：科济生物Claudin18.2 CAR-T细胞治疗实体瘤初获突破, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=07f5e2654866)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781437, encodeId=c0d61e8143787, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Nature Medicine：重磅！晚期癌症患者100%治疗反应！88%完全缓解！双特异性靶点CAR-T疗法1期临床试验结果公布, objectType=article, longId=215078, objectId=585a2150e865, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=585a2150e865, replyNumber=0, likeNumber=62, createdTime=2022-06-16, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=585a2150e865, moduleTitle=Nature Medicine：重磅！晚期癌症患者100%治疗反应！88%完全缓解！双特异性靶点CAR-T疗法1期临床试验结果公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=585a2150e865)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781493, encodeId=59f11e8149316, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=驯鹿生物全人源BCMA CAR-T细胞伊基仑赛注射液新增自身免疫性疾病适应症IND申请获受理, objectType=article, longId=728561, objectId=5e98e285619c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e98e285619c, replyNumber=0, likeNumber=93, createdTime=2023-01-01, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e98e285619c, moduleTitle=驯鹿生物全人源BCMA CAR-T细胞伊基仑赛注射液新增自身免疫性疾病适应症IND申请获受理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e98e285619c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781433, encodeId=6a6f1e81433d1, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=中国**CAR-T疗法获批上市之际，盘点CAR-T疗法发展历程！, objectType=article, longId=213096, objectId=9fe22130966a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fe22130966a, replyNumber=0, likeNumber=76, createdTime=2021-11-23, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fe22130966a, moduleTitle=中国**CAR-T疗法获批上市之际，盘点CAR-T疗法发展历程！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9fe22130966a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781431, encodeId=999f1e814313e, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Blood：糖皮质激素对CAR-T细胞疗法治疗的大B细胞淋巴瘤患者预后的影响, objectType=article, longId=212729, objectId=d16b212e29ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d16b212e29ab, replyNumber=0, likeNumber=78, createdTime=2022-01-21, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d16b212e29ab, moduleTitle=Blood：糖皮质激素对CAR-T细胞疗法治疗的大B细胞淋巴瘤患者预后的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d16b212e29ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781481, encodeId=67041e81481ab, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=双特异性抗体 epcoritamab 治疗 LBCL 取得积极结果，包括经 CAR-T 细胞疗法治疗失败的患者, objectType=article, longId=724362, objectId=8304e2436281, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8304e2436281, replyNumber=0, likeNumber=71, createdTime=2023-01-02, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8304e2436281, moduleTitle=双特异性抗体 epcoritamab 治疗 LBCL 取得积极结果，包括经 CAR-T 细胞疗法治疗失败的患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8304e2436281)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781467, encodeId=a1941e814679b, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Cancer Discovery：新型免疫检查点：可用来增强T细胞抗癌，还能让CAR-T对抗实体瘤, objectType=article, longId=300537, objectId=249330053eae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=249330053eae, replyNumber=0, likeNumber=78, createdTime=2022-04-10, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=249330053eae, moduleTitle=Cancer Discovery：新型免疫检查点：可用来增强T细胞抗癌，还能让CAR-T对抗实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=249330053eae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781448, encodeId=cd441e8144843, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=JACC：肿瘤治疗里程碑——注意万能CAR-T疗法的心肺不良事件！, objectType=article, longId=219460, objectId=63ca21946033, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63ca21946033, replyNumber=0, likeNumber=65, createdTime=2022-04-04, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63ca21946033, moduleTitle=JACC：肿瘤治疗里程碑——注意万能CAR-T疗法的心肺不良事件！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63ca21946033)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CAR-

2020-05-29

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Biomedicines：“肿瘤克星”CAR-T疗法再升级！未来或能实现百病皆可CAR-T

2022-10-12

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

天价神药“CAR-T”首例患者已出院，第二款也获批！

2022-05-14

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

突发：FDA暂停Beam公司基于碱基编辑的CAR-T疗法临床试验申请

2022-11-07

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Nature：CAR-T之父论文：效果超过十年，CAR-T真的彻底治愈了癌症

2022-09-10

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

由于患者死亡，CAR-T细胞疗法ATA2271的临床试验被暂停

2022-03-08

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

博生吉医药CD7靶向CAR-T细胞注射液获得美国FDA孤儿药资格认定

2022-02-04

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

AACR 2022：BioNTech的CAR-T细胞疗法治疗实体瘤，疗效确切

2023-01-25

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

【7月12日(周二)19:00星光奕奕】CAR-T中国病例分享——双打击病例专享会即将开始！

2022-07-15

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Blood：auto-HCT相比CAR-T疗法更适合用作获得部分缓解的DLCLC患者的巩固治疗！

2022-06-05

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Nature Chemical Biology ：疯狂的想法：武装CAR-T细胞，使其成为生产抗癌药物的“微型药房”

2022-05-29

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

CAR-T之父最新Nature论文：无需放化疗，合成IL-9受体增强T细胞疗法，治愈实体肿瘤

2022-10-14

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

科济药业发布2021年中期业绩自主研发 CAR-T候选品进入海外关键II期临床试验

2022-03-04

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Nat Med：科济生物Claudin18.2 CAR-T细胞治疗实体瘤初获突破

2023-01-12

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Nature Medicine：重磅！晚期癌症患者100%治疗反应！88%完全缓解！双特异性靶点CAR-T疗法1期临床试验结果公布

2022-06-16

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

驯鹿生物全人源BCMA CAR-T细胞伊基仑赛注射液新增自身免疫性疾病适应症IND申请获受理

2023-01-01

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

中国**CAR-T疗法获批上市之际，盘点CAR-T疗法发展历程！

2021-11-23

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Blood：糖皮质激素对CAR-T细胞疗法治疗的大B细胞淋巴瘤患者预后的影响

2022-01-21

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

双特异性抗体 epcoritamab 治疗 LBCL 取得积极结果，包括经 CAR-T 细胞疗法治疗失败的患者

2023-01-02

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Cancer Discovery：新型免疫检查点：可用来增强T细胞抗癌，还能让CAR-T对抗实体瘤

2022-04-10

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

JACC：肿瘤治疗里程碑——注意万能CAR-T疗法的心肺不良事件！

2022-04-04

科室
- - 订阅+
  - 更多科室
工具
服务